Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, discusses principal findings of the PROpel trial, which compared outcomes between olaparib plus abiraterone vs abiraterone alone in men with metastatic castration-resistant prostate cancer (mCRPC).
The ongoing PROpel trial investigated olaparib (Lynparza; AstraZeneca, Merck Sharp & Dohme) plus abiraterone (Zytiga; Janssen) vs abiraterone alone in men with metastatic castration-resistant prostate cancer, a patient group with a low 5-year survival rate who typically receives just 1 line of active treatment. The results presented at this year’s American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) demonstrate the combination’s quality-of-life and radiographic progression-free survival (rPFS) benefits; chiefly that it reduced risk of the latter by 34%. Overall rPFS was 24.8 vs 16.6 months, respectively, and there was a trend toward improved overall survival.
The American Journal of Managed Care® spoke recently with Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, about the PROpel trial findings presented at this year’s American Society of Clinical Oncology Genitourinary Cancers Symposium.
Transcript
Can you summarize the findings of the PROpel trial?
PROpel is a large randomized phase 3 trial, which included patients with first-line metastatic castrate-resistant prostate cancer, that we call mCRPC, that included a patient population which was not selected based on their HRR gene mutation status. PROpel was presented at ASCO GU and showed that olaparib in combination with abiraterone led to statistically significant and clinically meaningful improvements in radiographic PFS, which was a primary end point, with a reduction by 34% of the risk of disease progression or death in patients treated with olaparib and abiraterone compared to abiraterone plus placebo in the first-line setting.
Olaparib in combination with abiraterone improved radiographic PFS with a median of 8 months, extending the median rPFS for these first-line with metastatic castrate-resistant prostate cancer patients beyond 2 years. This is the longest PFS benefit seen to date in this setting. Importantly, this PFS benefit reported for olaparib plus abiraterone was irrespective of HRR gene mutation status.
I’d like also to note that the safety profile of the combination was consistent with the safety profile of each individual drug and the quality of life was maintained in the arm with olaparib plus abiraterone.
Bridging Education Gaps in Treatment for Scarring Alopecia With Innovative Approaches
March 28th 2025Crystal Aguh, MD, FAAD, Johns Hopkins School of Medicine faculty, highlights the critical need for comprehensive education on hair loss across diverse hair types, stressing the importance of understanding inflammatory pathways for developing targeted therapies.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Strategies for Improving Patient Access to Dermatology Care
March 22nd 2025Elizabeth Jones, MD, FAAD, highlights the persistent issue of insurance companies favoring expensive, newer medications over equally effective generics in dermatology, emphasizing the time-consuming prior authorization process and advocating for patient partnerships and systemic improvements.
Read More
Redefining Long COVID Care With Personalized Treatment
March 20th 2025To mark the 5-year anniversary of the COVID pandemic, The American Journal of Managed Care® spoke with Noah Greenspan, DPT, PT, CCS, EMT-B, cardiopulmonary physical therapist and director of the Pulmonary Wellness and Rehabilitation Center in New York City.
Read More